Pular para o conteúdo principal
Ranking Invest

EYPT - EyePoint Pharmaceuticals, Inc.

Segmento: HealthcareEyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Análise Ranking Invest

Valor de Mercado
$ 32.06 Mi
IVR
-14.76Índice proprietário de comparação relativa: -14,76.
IVR2
-20.29Leitura proprietária complementar: -2029%.
MLL
-20.29Leitura proprietária complementar: -2029%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 166.41 Mi

Dívida Líquida

-$ 110.46 Mi

L4T

-$ 306.64 Mi

MM4T

-11981.84%

Indicadores Básicos

ROE

-184.27%

Índices de Previsibilidade

Receita Líquida

F0.54

Lucro

C0.39

Margem

D0.82

Índices de Tendência

Receita Líquida

E-5.75

Lucro

G-9.06

Margem

G-8.89

Índices de Endividamento

DIV/PAT

-0.66

DIV/L4T

0.36

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.